Trusha Shah, MD
Interventional Pain Medicine · Lake Success, NYNPI 1699099036
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,307 of the $9,520 with a category attached, or 66.3%. 28 manufacturers reported payments, led by Boston Scientific at 36.0% of the total. Reporting peaked in 2022 at $4,476 and has fallen 80.5% since, to $872 in 2025.
Across 167 payments — averaging $57.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Relievant Medsystems, Inc.$2K
- Medtronic$1K
- SPR Therapeutics, Inc$673
- AbbVie$665
- Nevro Corp.$389
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$791%
- Travel & lodging$3,13333%
- Food & beverage$6,30766%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 29 | $3,426 |
| Relievant Medsystems, Inc. | 12 | $1,620 |
| Medtronic(2 entities) | 16 | $1,148 |
| SPR Therapeutics, Inc | 5 | $673 |
| AbbVie(2 entities) | 32 | $665 |
| Nevro Corp. | 10 | $389 |
| Abbott | 9 | $303 |
| Collegium Pharmaceutical, Inc. | 16 | $233 |
| GRT US Holding, Inc. | 4 | $163 |
| MML US, Inc. | 1 | $131 |
| Saluda Medical Americas, Inc. | 2 | $131 |
| Kowa Pharmaceuticals America, Inc. | 6 | $105 |
| Pfizer | 1 | $79 |
| Nalu Medical, Inc. | 3 | $59 |
| Bioventus LLC | 3 | $50 |
| Neuronetics, Inc. | 3 | $49 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Biodelivery Sciences International, Inc. | 2 | $33 |
| Globus Medical | 1 | $33 |
| IBSA Pharma Inc. | 2 | $32 |
| Averitas Pharma Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $23 |
| Virtus Pharmaceuticals LLC | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Forte Bio-pharma LLC | 1 | $18 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$2,635
- Superion Indirect Decompression System$1,860
- SPECTRA WAVEWRITER$621
- SPRINT PNS System$514
- KYPHON Balloon Kyphoplasty$503
- INTELLIS$278
- GENERAL PAIN MANAGEMENT$218
- GENERAL - THERAPIES$134
- ReActiv8$131
- PROCLAIM$129
- Senza Spinal Cord Stimulation System$126
- BOTOX$125
- Evoke$115
- Qutenza$114
How this compares
$9,520 in reported general payments places this provider in the 70th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 14 | $17,221 |
| Doxepin Hcl | 43 | $8,524 |
| Pregabalin | 167 | $5,470 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 233 | $5,309 |
| Lidocaine | 55 | $3,805 |
| Tizanidine Hcl | 322 | $3,299 |
| Gabapentin | 393 | $3,208 |
| Oxycodone Hcl | 114 | $2,455 |
| Fentanyl | 30 | $2,223 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 118 | $2,038 |
| Morphine Sulfate | 38 | $1,531 |
| Diclofenac Sodium | 157 | $1,191 |
| Duloxetine Hcl | 87 | $1,183 |
| Tramadol Hcl | 172 | $876 |
| Methylprednisolone | 101 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $665 | $17,22114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in Lake Success
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Hemant KaliaRochester$179K
- Martin FerrilloAlbany$164K
- George ChaseKew Gardens$102K
- Kimberly SackheimNew York$102K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Jafar SiddiquiWilliamsville$45K
- Alexander WeingartenSyosset$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.